NovaQuest finds value in drug commercialization

NovaQuest’s partners have found an interesting way to invest in pharmaceuticals at a time when neither the focus on healthcare nor the potential for treatment of rare diseases have been greater.

“We are investing in the late stages of R&D and commercialization of pharmaceutical products,” said Jonathan Tunnicliffe, the founding partner and chief investment officer of NovaQuest Capital Management.

We're not trying to underwrite the science. We're looking to interpret the data.

Jonathan tunnicliffe

The investment firm was founded as part of Quintiles, now known as . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available. Research articles require an Annual sub.

Get started

Ann C. Logue

Ann Logue is a writer specializing in business and finance. Her most recent book is "The Complete Idiot’s Guide: Options Trading" (Alpha 2016). She lives in Chicago.

Related Articles

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!